BR112017020484A2 - método para a fabricação de novo composto contendo nitrogênio ou sal do mesmo e intermediário de fabricação do novo composto contendo nitrogênio ou sal do mesmo - Google Patents

método para a fabricação de novo composto contendo nitrogênio ou sal do mesmo e intermediário de fabricação do novo composto contendo nitrogênio ou sal do mesmo

Info

Publication number
BR112017020484A2
BR112017020484A2 BR112017020484-3A BR112017020484A BR112017020484A2 BR 112017020484 A2 BR112017020484 A2 BR 112017020484A2 BR 112017020484 A BR112017020484 A BR 112017020484A BR 112017020484 A2 BR112017020484 A2 BR 112017020484A2
Authority
BR
Brazil
Prior art keywords
salt
containing compound
manufacturing methods
new nitrogen
those producing
Prior art date
Application number
BR112017020484-3A
Other languages
English (en)
Japanese (ja)
Other versions
BR112017020484B1 (pt
Inventor
Fukunaga Hirofumi
Shinjo Sachiko
Nakagawa Daisuke
SEKINE Shinichiro
Yamakawa Takayuki
Original Assignee
Fujifilm Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corporation filed Critical Fujifilm Corporation
Publication of BR112017020484A2 publication Critical patent/BR112017020484A2/pt
Publication of BR112017020484B1 publication Critical patent/BR112017020484B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D255/00Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/005Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/08Copper compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

um método para fabricar eficazmente um composto contendo nitrogênio, que é usado para fabricar um agente de tratamento para doenças relacionadas à integrina, ou um sal do mesmo, e um intermediário de fabricação do composto ou um sal do mesmo são fornecidos. um método para fabricar um novo composto contendo nitrogênio ou um sal do mesmo inclui (1) uma etapa de obter um composto representado pela fórmula [10] ou um sal do mesmo através de uma reação de amidação; e (2) uma etapa de desproteger o composto representado pela fórmula [10] ou um sal do mesmo.
BR112017020484-3A 2015-03-25 2016-03-25 Métodos para fabricar um composto contendo nitrogênio ou sal do mesmo e um complexo metálico, compostos contendo nitrogênio, complexos dos ditos compostos e composições farmacêuticas compreendendo os ditos complexos BR112017020484B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-062306 2015-03-25
JP2015062306 2015-03-25
PCT/JP2016/059729 WO2016153054A1 (ja) 2015-03-25 2016-03-25 新規な含窒素化合物またはその塩の製造方法およびそれらの製造中間体

Publications (2)

Publication Number Publication Date
BR112017020484A2 true BR112017020484A2 (pt) 2018-07-03
BR112017020484B1 BR112017020484B1 (pt) 2023-03-28

Family

ID=56977546

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020484-3A BR112017020484B1 (pt) 2015-03-25 2016-03-25 Métodos para fabricar um composto contendo nitrogênio ou sal do mesmo e um complexo metálico, compostos contendo nitrogênio, complexos dos ditos compostos e composições farmacêuticas compreendendo os ditos complexos

Country Status (24)

Country Link
US (3) US20180008583A1 (pt)
EP (3) EP3275883B1 (pt)
JP (1) JP6411634B2 (pt)
KR (1) KR102029746B1 (pt)
CN (2) CN107428755B (pt)
AU (4) AU2016237099C1 (pt)
BR (1) BR112017020484B1 (pt)
CA (1) CA2980268C (pt)
CO (1) CO2017010806A2 (pt)
CY (1) CY1124387T1 (pt)
DK (1) DK3275883T3 (pt)
ES (1) ES2877707T3 (pt)
HR (1) HRP20211031T1 (pt)
HU (1) HUE059670T2 (pt)
IL (4) IL254532B (pt)
LT (1) LT3275883T (pt)
MX (3) MX2017012184A (pt)
PL (1) PL3275883T3 (pt)
PT (1) PT3275883T (pt)
RS (1) RS62165B1 (pt)
RU (2) RU2720989C2 (pt)
SG (2) SG11201707899SA (pt)
SI (1) SI3275883T1 (pt)
WO (1) WO2016153054A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3929196T (pt) 2013-09-24 2023-09-11 Fujifilm Corp Composição farmacêutica de um novo composto contendo azoto ou seu sal, ou seu complexo de metal
AU2018229275B2 (en) 2017-02-28 2021-12-23 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2018160522A1 (en) 2017-02-28 2018-09-07 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin
TW202035400A (zh) 2018-08-29 2020-10-01 美商莫菲克醫療股份有限公司 抑制αvβ6整合素
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
CN113853220A (zh) * 2019-03-11 2021-12-28 生物相容英国有限公司 用于中枢神经系统肿瘤治疗的放射性微球
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound
JP2024500829A (ja) 2020-12-21 2024-01-10 アドヴァンスド アクセラレーター アプリケーションズ インターナショナル エセ.アー. 治療診断剤として使用するための放射性標識α-Vβ-3及び/又はα-Vβ-5インテグリンアンタゴニスト

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5941386B2 (ja) 1977-01-14 1984-10-06 株式会社紀文 高蛋白水産練製品様食品の製法
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
CA2272565A1 (en) 1996-11-27 1998-06-04 Du Pont Pharmaceuticals Company Integrin receptor antagonists
DE69829996T2 (de) * 1997-12-17 2006-02-23 Merck & Co., Inc. (A New Jersey Corp.) Integrin-rezeptor-antagonisten
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
JP2002532440A (ja) * 1998-12-18 2002-10-02 デュポン ファーマシューティカルズ カンパニー ビトロネクチン受容体拮抗剤薬剤
EP1140203B1 (en) * 1998-12-18 2007-05-23 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
AU780988B2 (en) 2000-01-24 2005-04-28 Merck & Co., Inc. Alpha V integrin receptor antagonists
EP1296678A2 (en) * 2000-06-21 2003-04-02 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
KR100854424B1 (ko) 2001-01-29 2008-08-27 3-디멘져널 파마슈티칼즈 인코오포레이티드 치환된 인돌 및 인테그린 길항제로서의 이들의 용도
KR101383655B1 (ko) 2010-05-24 2014-04-10 주식회사 바이오이미징코리아 트리카르보닐 테크네슘-99m 또는 레늄-188 표지 고리 알지디 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 질환의 진단 또는 치료용 약학적 조성물
FR2968999B1 (fr) * 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980364B1 (fr) * 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
WO2013048996A1 (en) 2011-09-30 2013-04-04 Ge Healthcare Limited Method for the purification of a peptide-based imaging agent precursor
DK2840080T3 (da) * 2012-04-17 2018-01-29 Fujifilm Corp Nitrogenholdig heterocyklisk forbindelse eller salt deraf
FR3001154B1 (fr) * 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
PT3929196T (pt) * 2013-09-24 2023-09-11 Fujifilm Corp Composição farmacêutica de um novo composto contendo azoto ou seu sal, ou seu complexo de metal

Also Published As

Publication number Publication date
RU2017133107A (ru) 2019-04-25
KR102029746B1 (ko) 2019-10-08
EP3275883A1 (en) 2018-01-31
CA2980268C (en) 2021-10-26
CO2017010806A2 (es) 2018-01-16
RU2767398C2 (ru) 2022-03-17
EP3275883B1 (en) 2021-06-02
SI3275883T1 (sl) 2021-09-30
CY1124387T1 (el) 2022-07-22
US20180008583A1 (en) 2018-01-11
IL254532B (en) 2021-12-01
AU2016237099A1 (en) 2017-10-19
EP3872079A1 (en) 2021-09-01
RU2017133107A3 (pt) 2019-04-25
CN107428755A (zh) 2017-12-01
EP4059936A1 (en) 2022-09-21
SG11201707899SA (en) 2017-10-30
RU2020115068A3 (pt) 2020-08-17
IL283288A (en) 2021-07-29
AU2020244580A1 (en) 2020-11-05
LT3275883T (lt) 2021-08-25
IL254532A0 (en) 2017-11-30
MX2017012184A (es) 2018-01-09
MX2023005703A (es) 2023-05-29
IL283289B (en) 2022-02-01
RU2020115068A (ru) 2020-06-26
WO2016153054A1 (ja) 2016-09-29
KR20170117577A (ko) 2017-10-23
IL283224A (en) 2021-07-29
AU2020244578A1 (en) 2020-11-05
AU2019246859A1 (en) 2019-10-31
JP6411634B2 (ja) 2018-10-24
AU2016237099C1 (en) 2023-01-19
EP3275883A4 (en) 2018-03-07
IL283288B (en) 2022-02-01
BR112017020484B1 (pt) 2023-03-28
CN111171026A (zh) 2020-05-19
JPWO2016153054A1 (ja) 2018-04-19
CA2980268A1 (en) 2016-09-29
US20240108607A1 (en) 2024-04-04
IL283224B (en) 2022-02-01
AU2016237099B2 (en) 2019-11-07
AU2019246859B2 (en) 2020-07-02
SG10201902609TA (en) 2019-04-29
DK3275883T3 (da) 2021-06-28
CN107428755B (zh) 2020-03-03
RS62165B1 (sr) 2021-08-31
CN111171026B (zh) 2023-03-03
AU2020244578B2 (en) 2022-08-11
PT3275883T (pt) 2021-07-07
AU2020244580B2 (en) 2022-08-11
RU2720989C2 (ru) 2020-05-15
ES2877707T3 (es) 2021-11-17
PL3275883T3 (pl) 2021-11-15
HRP20211031T1 (hr) 2021-10-01
MX2023005704A (es) 2023-05-29
IL283289A (en) 2021-07-29
HUE059670T2 (hu) 2022-12-28
US20210015802A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
BR112017020484A2 (pt) método para a fabricação de novo composto contendo nitrogênio ou sal do mesmo e intermediário de fabricação do novo composto contendo nitrogênio ou sal do mesmo
MX2019012942A (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
EA201890522A1 (ru) Способ получения противогрибковых соединений
BR112016028773A2 (pt) processos para preparação de compostos antivirais
BR112016024936A2 (pt) moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
NZ721645A (en) Compounds for use as gpr120 agonists
BR112015021386A2 (pt) moduladores de ácido biciclo [2.2.2] gpr120
EA201892515A1 (ru) Стероидные 6,7-бета-эпоксиды в качестве интермедиатов
SG11201906688VA (en) Novel ester compounds, method for the production thereof and use thereof
MA50169A (fr) Procédé de production d&#39;un électrocatalyseur
BR112016025024A2 (pt) ?processo para preparar compostos ceto, e, uso de farnesil acetona?
MX369556B (es) Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac).
EA201791645A1 (ru) Новые соли и полиморфы scy-078
BR112019001447A2 (pt) método de produção para composto pirazol-amida
CL2019002636A1 (es) Agente para el control de enfermedades en plantas.
BR112015024859A2 (pt) processo e intermediários para a preparação de pregabalina
BR112016018594B8 (pt) Método para produção do derivado de 2-aciliminopiridina
EA201990362A1 (ru) Аналог вортиоксетина и его применение и получение
BR112018005930A2 (pt) processo de preparação de compostos de indolina e um sal de indolina
BR112018003313A2 (pt) novo derivado de catecol e composição farmacêutica compreendendo o mesmo
AR100095A1 (es) Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico
EA201691465A1 (ru) Средство для лечения сердечно-сосудистых заболеваний
PH12018500176A1 (en) Ameliorating agent for detrusor hyperactivity with impaired contractility
PH12017501560A1 (en) Tetrahydropyranyl benzamide derivatives

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/03/2016, OBSERVADAS AS CONDICOES LEGAIS